Guillaume Baneyx

Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration

Guillaume Baneyx, Neil Parrott, Christophe Meille et al. · European Journal of Pharmaceutical Sciences · 2014 · 80 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™

Aki T. Heikkinen, Guillaume Baneyx, Antonello Caruso et al. · European Journal of Pharmaceutical Sciences · 2012 · 74 citations

Medicine, Pharmacokinetics, Pharmacology +13

Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma

Cora N. Sternberg, Frede Donskov, Naomi B. Haas et al. · Clinical Cancer Research · 2018 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.

Aitana Calvo, Heikki Joensuu, Martin Sebastian et al. · Journal of Clinical Oncology · 2018 · 43 citations

Medicine, Oncology, Pharmacology +17

Population pharmacokinetics–pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex

François Pierre Combes, Guillaume Baneyx, Neva Coello et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2018 · 16 citations

Medicine, Pharmacokinetics, Pharmacology +12